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Abstract
Congenital tufting enteropathy (CTE) is a devastating diarrheal
disease seen in infancy that is typically associated with villous
changes and the appearance of epithelial tufts. We previously
found mutations in epithelial cell adhesion molecule (EpCAM)
to be causative in CTE. We developed a knock-down cell
model of CTE through transfection of an EpCAM shRNA
construct into T84 colonic epithelial cells to elucidate the
in vitro role of EpCAM in barrier function and ion transport.
Cells with EpCAM deficiency exhibited decreased electrical
resistance, increased permeability, and decreased ion transport.
Based on mutations in CTE patients, an in vivo mouse model
was developed, with tamoxifen-inducible deletion of exon 4 in
Epcam resulting in mutant protein with decreased expression.
Tamoxifen treatment of EpcamΔ4/Δ4 mice resulted in patho-
logical features of villous atrophy and epithelial tufts, similar
to those in human CTE patients, within 4 days post induction.
EpcamΔ4/Δ4 mice also showed decreased expression of tight
junctional proteins, increased permeability, and decreased ion
transport in the intestines. Taken together, these findings reveal
mechanisms that may underlie disease in CTE.
Key messages
& Knock-down EpCAM cell model of congenital tufting
enteropathy was developed.
& In vivo inducible mouse model was developed resulting in
mutant EpCAM protein.
& Cells with EpCAM deficiency demonstrated barrier and
ion transport dysfunction.
& Tamoxifen-treated EpcamΔ4/Δ4 mice demonstrated patho-
logical features.
& EpcamΔ4/Δ4 mice showed improper barrier function and
ion transport.
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Introduction
Congenital tufting enteropathy (CTE) is a severe intractable
diarrheal disease presenting in the neonatal period with chron-
ic watery diarrhea, imbalances in electrolytes, and impaired
growth. The prevalence of CTE is thought to be 1/50,000–1/
100,000 live births in Western Europe [1]. CTE is an autoso-
mal recessive disease, often seen in families with a history of
consanguinity [2]. A diagnosis of CTE is made with recogni-
tion of changes in the villi of the small intestinal epithelium.
CTE is usually accompanied by villous atrophy, crypt hyper-
plasia, formation of focal epithelial tufts (bunching of
enterocytes) in the small intestinal and colonic mucosae, and
absent or mild inflammation [3, 4]. CTE often results in
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intestinal failure. Patients must rely on total parenteral nutri-
tion to receive necessary caloric intake for growth and devel-
opment, as no therapies exist at this time [1]. Periods of
prolonged parenteral nutrition are not optimal due to both
quality of life and health considerations, such as vascular
complications and liver disease [5, 6].
Epithelial cell adhesion molecule (EpCAM) is a cell adhe-
sion molecule involved in cellular communication [7].
EpCAM was first recognized as an antigen overexpressed
on human carcinoma cells in the digestive tract, breasts,
and kidneys [8]. In healthy adult tissue, EpCAM is typi-
cally expressed on the basolateral surface of simple and
pseudostratified epithelial cells in the gastrointestinal, re-
spiratory tracts, and reproductive systems. EpCAM has
been shown to be involved in cellular adhesion and pro-
liferation, but its exact role in intestinal function has not
been fully elucidated [9, 10].
Sivagnanam et al. first identified mutations in EpCAM as
causative in CTE, and this has been confirmed by other
groups [11–14]. CTE patients express mutant EpCAM at
significantly decreased levels in biopsied intestinal tissue
as seen by immunohistochemistry and Western blot [11].
Staining with antibodies to EpCAM has been established
as a diagnostic tool in CTE [4, 15].
To maintain intestinal homeostasis, normal barrier function
is essential. The barrier formed between epithelial cells is
partly comprised of the apically located tight junction com-
plex. Tight junctional proteins include occludin, claudins,
junctional adhesion molecules (JAMs), and zonula occludens
(ZO) proteins [9]. ZO proteins link the membrane proteins,
occludin and claudins, to the actin cytoskeleton. In the ab-
sence of ZO’s, cells fail to form effective tight junctions [16,
17]. Occludin is important in regulating the paracellular bar-
rier via binding of its C-terminus to ZO-1, allowing localiza-
tion of occludin to the tight junctions [18, 19]. EpCAM has
also previously been shown to be involved in the formation of
tight junctions through the recruitment and regulation of
claudin proteins [9, 15, 20]. In this study, we investigated
how disruption of EpCAM affects tight junctions and barrier
function, as they relate to the observed phenotype of CTE.
The T84 colonic adenocarcinoma cell line has been widely
used as a model for studies of epithelial electrolyte transport
and barrier function. When T84 cells are grown as a mono-
layer, they form tight junctions and display secretagogue-
sensitive chloride secretion as a model for secretory cells
within the colonic crypt [21]. In this study, we generated an
shRNA transfected T84 cell line in which EpCAM was stably
knocked-down (KD) to elucidate the role of EpCAM in tight
junction formation and secretory function. As EpCAM is
expressed in both the small and large intestines [4], knock-
down of EpCAM in colonic T84 cells is an appropriate in vitro
model to investigate the mechanism of intestinal dysfunction
in the emergence of diarrhea with EpCAM deficiency.
EpCAM is highly conserved in mammals, and its distribu-
tion in mice is similar to that of human EpCAM with highest
expression in the intestines [22]. We generated an in vivo
inducible mouse model of CTE with a mutation that corre-
sponds to a common EpCAM mutation found in patients, in
which a homozygous G>A substitution at the donor splice site
of exon 4 results in a mRNA splice product lacking exon 4
[15, 23]. Unlike our previousmodel [15], inducible deletion of
exon 4 allows for extended survival, permitting us to further
elucidate the in vivo role of EpCAM in barrier formation and
electrolyte transport. With this mouse model, we sought to
validate the T84 cell model in studying the mechanisms of
CTE and to further characterize the intestinal effects of
mutant EpCAM from a post developmental standpoint.
We hypothesized that both the KD cells and mutant murine
model would show attenuated expression of tight junctional
proteins, altered ion transport, and increased permeability of
the intestinal barrier.
Methods
Development of inducible epcamΔ4/Δ4 mice
The Epcam targeting construct was developed as previously
described [15]. Mice homozygous for the mutant Epcam Δ4
construct, in which the neomycin-resistant positive selection
marker had been previously removed via Flip recombinase,
were bred to B6.Cg-Tg(Cre/Esr1)5Amc/J mice obtained
from Jackson Labs, Bar Harbor, ME. This allowed for
Cre-LoxP recombination and efficient deletion of exon 4
in Epcam following administration of tamoxifen [24].
Mice were orally gavaged with 25 mg/kg tamoxifen free
base (MP Biomedicals, Solon, OH) in 90 % sunflower
seed oil fromHelianthus annus (Sigma, St. Louis, MO) /10 %
ethanol once daily for two consecutive days, generating
EpcamΔ4/Δ4 mice. EpcamWT/WT mice orally gavaged with
tamoxifen (as above) served as controls for all experiments
(WT). All studies were approved by the UCSD Institutional
Animal Care and Use Committee.
Cell culture
T84 cells were cultured in 1:1 Dulbecco’s modified Eagle’s
Medium/F-12 Ham’s medium with 15 mM L-glutamine
(Mediatech Inc., Manassas, VA), 5 % bovine calf serum
(Invitrogen, Grand Island, NY), 1 % penicillin-streptomycin
(Mediatech Inc.) and maintained according to a standard
protocol [25].
Specific KD of Epcam in cells was accomplished with
SureSilencing shRNA plasmids (SABiosciences Corporation,
Frederick, MD). High efficiency KD was achieved via
Amaxa electroporation. Two microgram of shRNA plasmid
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was added to T84 cells, and electroporation was performed
according to manufacturer recommendations. Cells were
grown in selective media (500 μg/ml G-418 sulfate,
Mediatech Inc.) for 3 weeks to generate stable transfectants.
In order to retain the KD phenotype in cells transfected
with shRNA, 40 μg/mL of G418 sulfate was retained in
the medium thereafter.
For resistance and permeability studies, cells were grown
on semipermeable 12-mm Millicell-HA culture plate inserts
with 0.5×106 cells added per insert. Cells were maintained
in media as above. Cell culture media was changed every
3 days for approximately 2 weeks until cells formed a
monolayer [25].
Electrical resistance
To assess monolayer integrity, a voltohmmeter (World Precision
Instruments, Sarasota, FL) was used to measure transepithelial
electrical resistance (TER) across themonolayer. Themonolayer
was considered mature when the TER of control T84 cells
reached a peak value (600 ohms.cm2). TERs were recorded for
control and KD cell monolayers every day until 2 days past
maturity, which was at about 2 weeks.
Four days after initial tamoxifen induction, EpcamΔ4/Δ4
and control mice were sacrificed by cervical dislocation and
full-thickness segments of distal ileum and proximal colon
were mounted in Ussing chambers (Physiological Instru-
ments, San Diego, CA). A transepithelial current pulse of
10 μA was administered to assess tissue viability, and TER
was calculated using Ohm’s law.
Permeability
When a mature monolayer was confirmed by TER measure-
ment of controls, macromolecular permeability was assessed
in control and KD T84 cell monolayers. Fluorescein isothio-
cyanate (FITC)-dextran 4kD (Sigma) was added to the apical
medium bathing semipermeable inserts at a final concentra-
tion of 1 mg/mL. At each hour thereafter, for 3 h, the
basolateral medium was sampled. For tissue studies, FITC-
dextran was added to the serosal side (1 mg/mL) of tissue
segments mounted in Ussing chambers and the mucosal me-
dium sampled at hourly intervals thereafter. All samples were
analyzed for FITC levels with a Spectramax M2 Absorbance
Microplate reader (Molecular Devices, Sunnyvale, CA) cali-
brated with appropriate standards.
Ion transport
To assess ion transport responses, T84 cells grown on semi-
permeable membranes and distal ileum and proximal colon
tissues from EpcamΔ4/Δ4 mice and control animals were
mounted into Ussing chambers according to protocol [26]
and bubbled with 95, 5 % CO2. Once mounted in the cham-
bers (cell window area: 0.6 cm2, mouse tissue window area:
0.09 cm2), inserts/tissue were allowed 20min of equilibration.
Changes in short circuit current (ΔIsc) were measured after
sequential exposure to forskolin (fsk) and carbachol (cch),
which are cAMP- and calcium-dependent chloride secreta-
gogues, respectively.
Western blotting
T84 cell monolayers were suspended in ice-cold lysis buffer
(50 mM Tris, 150 mM NaCl, 0.1 % SDS, 0.5 % sodium
deoxycholate, 20 μM NaF, 1 mM EDTA, 1 μg/ml antipain,
1 μg/ml pepstatin, 1 μg/ml leupeptin, 1 mM NaVO3,
and 100 μg/ml phenylmethylsulfonyl fluoride), vortexed
thoroughly, and lysed using a 22-gauge needle. The
lysates were centrifuged at 10,000 rpm for 10 min to
remove insoluble material. An aliquot was removed
from each sample to determine protein concentration
using the Bio-Rad (Hercules, CA) protein assay, according
to the instructions of the manufacturer, and analyzed by
Spectramax M2 Absorbance Microplate reader. Samples
were resuspended in loading buffer (50 mM Tris -pH
6.8, 2 % SDS, 100 mM dithiothreitol, 0.2 % bromphenol
blue, and 20 % glycerol).
Distal ileum and proximal colon were placed in nonyl
phenoxypolyethoxyethanol-40(NP-40) buffer containing
0.9 % NaCl, 10 % glycerol, 50 mM Tris pH2.8, 0.1 %
NP40, 5 mM EDTA, 20 μM NaF, 1 μg/ml antipain, 1 μg/ml
pepstatin, 1 μg/ml leupeptin, 1 mM NaVO3, and 100 μg/ml
phenylmethylsulfonyl fluoride and lysed using a mini bead
beater (BioSpec Products, Bartlesville, OK). The lysate was
centrifuged and the supernatant containing the protein was
removed, with protein concentration determined as above.
Samples were resuspended in loading buffer.
Cell and tissue lysates were diluted with a 5 to 1 ratio
of lysate to loading buffer and loaded onto Mini-Protean
TGX precast gels (BioRad), electrophoresed, then trans-
ferred onto a nitrocellulose membrane. Membranes were
blocked with 5 % bovine serum albumin/TBST for studies
of occludin, EpCAM, and ZO-1, and 5 % dry milk/TBST
for studies of the Na/K/2Cl cotransporter, NKCC-1 and
the cystic fibrosis transmembrane conductance regulator,
CFTR.
Western blotting was performed using mouse antibodies to
occludin (Invitrogen), goat antibodies to NKCC-1 (Santa Cruz
Biotechnology, Dallas, TX), rabbit antibodies to ZO-1
(Invitrogen), CFTR (GenTex, Zeeland, MI), and EpCAM
(abcam, Cambridge, MA) diluted at 1:1000. A mouse mono-
clonal antibody to β-actin at 1:2000 (Sigma) was used to
correct for loading. Horseradish peroxidase-conjugated anti-
mouse, anti-rabbit, and anti-goat IgG (Cell Signaling Tech-
nologies, Beverly, MA) secondary antibodies were used at
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1:2000 dilutions. A semiquantitative measurement of band
density was performed using Scion Image for Windows
software.
Q-PCR
Total RNA from T84 cells was isolated using RNeasy
Mini kits (Qiagen, Valencia). Distal ileum and proximal
colon tissues were excised and homogenized in TRIzol
(Invitrogen) with a bead beater. RNA was extracted with
chloroform, followed by 70 % ethanol and an RNeasy
Mini kit (Qiagen). First strand cDNA was synthesized with
iScript cDNA Synthesis kit (Bio Rad) using the recom-
mended protocol. Real-time PCR reactions were set up using
FastStart Universal SYBRGreenMasterMix (Invitrogen) and
thermal cycling performed on a StepOnePlus Real-Time PCR
System using Step One software v2.0 (Applied Biosystems,
Carlsbad, CA). Primers were designed and obtained from IDT
(Integrated DNATechnologies, Coralville, IA, Supp. Table 1).
All primers were diluted to a concentration of 100 μM. Glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) and villin
were used as endogenous controls.
Immunofluorescence
Control and EpCAM KD T84 cells were grown on glass
coverslips sterilized with 70 % ethanol and a Bunsen burner
flame. Cells were washed with PBS and fixed with 3.7 %
paraformaldehyde for 30 min at room temperature. Tissue
sections were blocked using 5 % bovine serum albumin/PBS
and then incubated overnight at 4 °C with antibodies to actin
(Sigma), NKCC-1 (Santa Cruz Biotechnology), or EpCAM
(abcam) diluted at 1:200. Secondary detection was performed
by incubation with Alexa Fluor 568-conjugated donkey anti-
mouse or Alexa Fluor 568-conjugated goat anti-rabbit anti-
bodies, Alexa Fluor 647 donkey anti-goat all diluted at 1:200,
and Hoechst 33258 (Invitrogen).
Distal ileum and proximal colon were excised and fixed
with 4% paraformaldehyde for 24 h at room temperature, then
paraffin-embedded and sectioned onto glass slides. De-
paraffination was performed and samples were heated in
10 mM sodium citrate buffer. Blocking was performed as
previously described [27]. Tissue sections were incubated
with antibodies (1:200) to NKCC1 (Santa Cruz Biotechnology)
or actin (Sigma) for 1 h. Secondary detection was performed
using secondary, Alexa Fluor 568-conjugated donkey anti-
mouse (1:200) or Alexa Fluor 488-conjugated donkey anti-
rabbit (1:200) antibodies and Hoechst 33258 (Invitrogen). Im-
aging was performed using a Zeiss LSM 510 confocal imaging
system, 25× Plan-Apo, 0.8 Numerical aperture. The imaging
medium used was ProLong gold anti-fade reagent (Invitrogen),
and imaging was done at room temperature using Zeiss LSM
Image Acquisition software.
Statistical analysis
Linear regression, one-way Anova, and t test analyses were
performed using GraphPad Prism version 4.00 for Windows
(GraphPad Software, La Jolla, CA).
Results
Knock-down of EpCAM in T84 cells
To determine the role of EpCAM in barrier function, we
knocked-down this protein in T84 cells using shRNA that
targeted EpCAM. KD cells showed decreased levels of
EpCAM by Western blot compared to control cells (Con)
treated with scrambled shRNA (Fig. 1a).
Confocal microscopy was used to compare the expression
and localization of EpCAM between KD and control T84
cells. As expected, EpCAM fluorescence was reduced in
KD cells (Fig. 1b), but the residual EpCAM in KD cells still
appeared to localize to intercellular contacts, as seen in control
cells.
Mutation of Epcam in mice results in intestinal defects
Following oral gavage with tamoxifen, small intestinal tissue
from EpcamΔ4/Δ4 mice was processed for Western blotting,
revealing a significant decrease in EpCAM expression com-
pared to controls (Fig. 1c). Small intestinal tissue from
EpcamΔ4/Δ4 and control mice was evaluated histologically.
Tissue from EpcamΔ4/Δ4 mice displayed several characteris-
tics similar to those seen in CTE patients and in our previous
constitutive mouse model [15], including villous atrophy and
bunching of enterocytes leading to the formation of tufts on
villi (Fig. 1d). Quantitatively, there was a significant decrease
in villous length in EpcamΔ4/Δ4 mice (Fig. 1e).
Knock-down of EpCAM results in barrier dysfunction
KD and control T84 monolayers were evaluated for TER,
permeability, and expression of tight junctional proteins.
TER was significantly decreased in KD cells (Fig. 2a) com-
pared to control cells receiving scrambled shRNA. The two
cell populations were also examined for macromolecular per-
meability using FITC-dextran. At each time point examined,
KD cells showed significant increases in FITC-dextran per-
meability compared to controls (Fig. 2b).
To investigate possible mechanisms that might explain the
decrement in barrier function when EpCAM was decreased,
levels of occludin and ZO-1 were examined. Expression of
both proteins was decreased in KD compared to control cells
(Fig.3a, b). At the mRNA level, expression of occludin was
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significantly decreased in KD cells (Fig. 3c), but there was no
significant effect of EpCAM KD on mRNA levels for ZO-1
(Fig. 3d).
To determine towhat extent the functional effects of EpCAM
KD in T84 cells were also seen in vivo, we studied barrier
function in intestinal segments obtained from tamoxifen-
treated EpcamΔ4/Δ4 mice and control animals. Permeability to
FITC-dextran was significantly higher in both distal ileum
and proximal colon from EpcamΔ4/Δ4 mice than in control
animals (Fig. 4a).
Fig. 1 Targeting EpCAM in cell and murine models results in reduced
EpCAM expression and morphological changes in murine intestine. a
Quantification and Western blot of EpCAM in control and KD-EpCAM
T84 cells (n=3). b Fluorescent immunohistochemistry reveals a decrease in
EpCAM fluorescence in KD-EpCAMT84 cells. EpCAM green, DAPI blue
(n=3). c Quantification and Western blot of EpCAM in inducible murine
model (n=3). d H&E staining of ileum shows morphological changes in
villi and crypts of EpcamΔ4/Δ4 mice. e EpcamΔ4/Δ4mice exhibit decreased
villous length (n=6). Fold changes were compared using Student’s paired t
test. *p<0.05, bars indicate standard error of the mean (SEM)
Fig. 2 Knockdown of EpCAM
attenuates TER and permeability.
a TER of T84 cells was decreased
in KD-EpCAM cells (*p<0.05,
n=8). b FITC-4kD permeability
was significantly increased in
KD-EpCAM cells (*p<0.0001,
student’s paired t test, n=6).
Bars indicate SEM
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To corroborate these findings, the expression of tight junc-
tional proteins was measured in the murine model. Western
blot revealed that expression of occludin and ZO-1 was de-
creased in the small intestine of EpcamΔ4/Δ4 mice compared
with controls (Fig. 4b, c). On the other hand, evaluation of
mRNA for ZO-1 by qPCR showed comparable expression
levels in EpcamΔ4/Δ4 and control animals while there was
decreased expression of mRNA for occludin (Fig. 4d), con-
sistent with findings in the in vitro model described above.
Knock-down of EpCAM results in ion transport dysfunction
To explore potential mechanisms for the severe diarrhea in
CTE, we studied chloride secretion in T84 KD cells compared
with controls. Cell monolayers were mounted in Ussing
chambers and stimulated with fsk and cch (Fig. 5a). Changes
in short circuit current (ΔIsc), reflective of net chloride secre-
tion in response to these agonists, were measured. Surprising-
ly, chloride secretion evoked by either fsk or cch was reduced
in cells with reduced EpCAM expression compared to control
cells (Fig. 5a).
To investigate a possible basis for the reduction in chloride
secretion, the expression of key transporters, CFTR and
NKCC-1, was studied by Western blotting. There was no
appreciable difference in the expression of CFTR between
control and KD cells (Fig. 5b). In contrast, levels of NKCC-
1 were significantly decreased in KD cells compared with
controls (Fig. 5c). Further investigation of NKCC-1 was per-
formed with confocal microscopy. A decrease in fluorescence
for NKCC-1 was observed in KD cells, although the trans-
porter apparently remained confined to the basolateral domain
as seen in control cells (Fig. 5d). Interestingly, we also found
that the actin in KD cells was disorganized and aggregated
into clumps vs. the typical cobble stone pattern of actin
localization seen in control cells (Fig. 5d).
Investigation of ion transport in tissues from EpcamΔ4/Δ4
mice revealed similar findings. Sections of distal ileum and
proximal colon were mounted in Ussing chambers and stim-
ulated with fsk. Although both absorptive and secretory trans-
port processes are present in these tissues, chloride secretion
should be the predominant electrogenic process in these seg-
ments, particularly in response to fsk, and so, ΔIsc can be
taken as a proxy for this transport event. In both segments, the
chloride secretory response to fsk was reduced in tissues from
EpcamΔ4/Δ4 mice following tamoxifen treatment compared to
control animals (Fig. 6a).
CFTR and NKCC-1 were analyzed by Western blot in
these tissues, showing no significant difference in the expres-
sion of CFTR (Fig. 6b), but significantly decreased expression
of NKCC-1 within the distal ileum (Fig. 6c). Immunohisto-
chemistry revealed decreased fluorescence for NKCC-1
throughout the small and large intestines in EpcamΔ4/Δ4 mice
compared to controls, although residual NKCC-1 remained
localized to the basolateral membrane as seen in control mice
(Fig. 6d).
Discussion
Congenital tufting enteropathy, a disorder caused by muta-
tions in EpCAM, results in a serious clinical phenotype that is
debilitating to children. Through the use of in vitro and in vivo
models of CTE, we have demonstrated that mutations in
EpCAM result in its reduced expression, also leading to intes-
tinal epithelial dysfunction encompassing compromised
Fig. 3 Tight junction proteins are decreased in KD-EpCAM cell lines. a
Quantification and Western blot of occludin in control and KD-EpCAM
cells (n=3). b Quantification and Western blot of ZO-1 in control and
KD-EpCAM cells (n=3). c Occludin mRNA levels by qPCR in KD-
EpCAM cells compared with control T84 cells (n=3). d ZO-1 RNA
levels by qPCR in KD-EpCAM cells compared with control T84 cells
(n=3). Fold changes were compared using Student’s paired t test.
*p<0.05, bars indicate SEM
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resistance, macromolecular permeability, tight junction integ-
rity, and changes in ion transport.
Although the T84 cell line cannot model absorptive trans-
port in the intestine, these cells form a polarized monolayer
with tight junctions and display robust chloride secretory
responses to both cAMP- and calcium-dependent agonists
[28, 29]. KD of EpCAM in T84 cells significantly impaired
their ability to develop normal barrier properties. Similarly, in
our inducible mouse model, EpcamΔ4/Δ4 mice exhibited a
leaky epithelial barrier. In light of these results and previous
knowledge that claudin proteins are downregulated in the
presence of mutant EpCAM [15, 20], we evaluated expression
of key tight junction proteins to explore the mechanism of
barrier dysfunction. ZO-1, a protein essential for the assembly
of tight junctions in epithelial cells [16, 30] is known to
interact with the C-terminus of occludin [31]. Occludin is
Fig. 4 Mutated Epcam in mice has deleterious effects on permeability
and decreases tight junction proteins. a Permeability of FITC-4kD is
significantly increased in both distal ileum and proximal colon
(*p<0.0001, n=3). b Occludin levels in the proximal colon and distal
ileum byWestern blot and quantification of fold change (*p<0.05, n=3).
cZO-1 levels in the distal ileum byWestern blot and quantification of fold
change (*p<0.05, n=4). dOccludin and ZO-1 mRNA levels by qPCR in
the small intestines of EpcamΔ4/Δ4 mice (*p<0.05, n=4). Fold changes
were compared using Student’s paired t test. Bars indicate SEM
J Mol Med (2015) 93:535–545 541
involved in tissue resistance as evidenced by previous studies
showing occludin-dependent increases in TER [32]. Protein
levels for both occludin and ZO-1 were decreased when
EpCAM levels were reduced in both our cell and mouse
models. For occludin, a concomitant decrease in mRNA sug-
gests EpCAM may stimulate its transcription through a direct
or indirect mechanism. On the other hand, a post-
transcriptional impact of EpCAM on ZO-1 must presumably
occur based on the unchanged RNA levels. This warrants
future studies into the protein-protein interactions of EpCAM,
as it has been previously shown to control the composition
and function of tight junctions [33].
We also studied whether a relative deficit in EpCAM
expression would impact ion transport, hypothesizing that an
increase in chloride secretion might explain diarrheal symp-
toms seen in CTE. Changes in ion transport were studied
using agonists of chloride secretion: fsk, an activator of the
cAMP-dependent pathway causing secretion through CFTR
[28], and cch, an activator of a Ca2+ dependent pathway that
opens a basolateral K+ channel, but also results in chloride
Fig. 5 Knockdown of EpCAM results in decreased ion transport. aΔIsc
in response to forskolin (fsk) and carbachol (cch) show decreased
responses in KD-EpCAM cells (*p<0.0001, n=6). b CFTR measured by
Western blot and quantified for fold change (n=3). cNKCC-1measured by
Western blot and quantified for fold change (*p<0.05, n=3). d Fluorescent
immunohistochemistry of NKCC-1 showed normal localization but
decreased fluorescence in KD-EpCAM cells. NKCC-1 green, actin red,
DAPI blue (n=4). Data were compared using Student’s paired t test. Bars
indicate SEM
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secretion [29]. However, contrary to our hypothesis, a reduc-
tion in EpCAM was accompanied by a reduction in chloride
secretion in both T84 cells and EpcamΔ4/Δ4 mice. This was
apparently secondary to a reduction in NKCC-1, but not
CFTR, expression. A decrease in the Cl− loading ability of
epithelial cells resulting from the decrease in NKCC-1 may
explain the decreases in ion transport [34]. Although our
findings cannot explain diarrheal symptoms in CTE, they
are consistent with reductions in both cAMP- and calcium-
dependent chloride secretion that have been reported in vari-
ous models of colitis [35, 36]. This reduction in chloride
secretion has been speculated to contribute to defects in host
Fig. 6 Mutated EpCAM causes ion transport dysfunction in the murine
model. a ΔIsc in response to forskolin in the distal ileum and proximal
colon was decreased in mice with mutant EpCAM (n=5). b CFTR in the
small intestine measured by Western blot and quantified for fold change
(n=3). c Protein expression and quantification of NKCC-1 in the small
intestines (n=3). d Immunofluorescence of NKCC-1 in the small and
large intestines shows decreased fluorescence in mice with mutated
EpCAM (n=3). NKCC-1 green, DAPI blue, SI small intestine, LI large
intestine. Data were compared using Student’s paired t test. *p<0.05,
bars indicate SEM
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defense by reducing the normal flushing of crypt contents,
thereby protecting the vulnerable stem cell niche [37]. The
precise mechanisms whereby a reduction of EpCAM reduces
NKCC-1 expression remain to be identified. It will also be of
interest to study the impact of decreased EpCAM on the
expression of absorptive transporters in the murine model as
a possible explanation for fluid loss, as has been reported in
some models of infectious diarrhea [38, 39].
While examining NKCC-1 localization in EpCAM KD
T84 cells using immunohistochemistry, we found a severe
disorganization of the actin cytoskeleton. ZO-1 is important
in linking tight junction proteins to the actin cytoskeleton and
is also known to associate with α-catenin [17, 40]. Recently,
disruption of the ZO-1/α-catenin complex was similarly as-
sociated with actin disorganization [41]. It is possible that
EpCAM regulates assembly of the ZO-1/α-catenin complex,
which could account for the disorganization observed when
EpCAM is deficient. Additionally, EpCAM is also known to
interact with the actin cytoskeleton directly via α-actinin [42].
Our study in cell and murine models has elucidated an
important role for EpCAM in maintaining proper intestinal
function. In the case of mutated or absent EpCAM, not only is
it not possible for a proper barrier to bemaintained, but there is
also dysregulation of ion transport. EpCAM is expressed in
other organ systems of the body, such as the respiratory tract
and kidney, yet these organs do not display obvious dysfunc-
tion in CTE patients or our murine model [8]. Although we
found decreases in important tight junctional proteins in the
small bowel and colon, it may be that EpCAM participates in
tissue-specific regulatory pathways or that EpCAM itself is
regulated by another pathway outside of the gut that permits
normal function of extraintestinal tight junctions even in the
absence of EpCAM. Additionally, the intestine-specific pa-
thology may be explained by EpCAM’s differential expres-
sion levels throughout the body, with areas such as the small
intestines and colon having the highest expression [43]. Pre-
vious studies have shown increased levels of occludin and
ZO-1 in lung tissue compared to the colon and small bowel
[44]. Thus, some tissues in which EpCAM is normally
expressed may have tight junctions that are more resistant to
the loss of a regulatory molecule such as EpCAM.
Our study nevertheless builds on previous understanding of
the function of EpCAM in the intestine to demonstrate that
EpCAM likely plays a critical role in the formation of tight
junctions and the regulation of specific ion transporters in
intestinal epithelial cells. Moreover, similar findings in the
cell and murine models suggest that the cell model of CTE
can be deployed for efficient mechanistic studies of CTE. Our
findings are also suggestive that, in CTE, the inability to form
a robust barrier outweighs secretory problems, possibly
explaining the diarrheal phenotype. Future studies examining
the role of EpCAM in tight junction formation and how it
associates with other cell adhesion molecules should be
undertaken. Our findings of actin reorganization likewise
warrant further investigation of EpCAM’s role in regulating
the cytoskeleton. We aim to achieve a better understanding of
how EpCAM disrupts the intestinal barrier in order to develop
therapeutic strategies for CTE.
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